Glenn Saldanha

Glenmark Pharma SA Completes its Phase-I Clinical Trials of GRC 15300

Glenmark Pharma SA Completes its Phase-I Clinical Trials of GRC 15300Glenmark Pharmaceuticals SA has successfully completed Phase-I clinical trials of its new molecule, GRC 15300, which has been developed for treatment of neuropathic pain. GRC 15300 is a first in–class inhibitor for treatment of pain.

Chairman and Managing Director of the company, Mr. Glenn Saldanha, said that GRC 15300 is the first TRPV3 inhibitor across the globe. Glenmark done its Phase-1 analysis in UK and Saldanha said that they have plans to start the clinical proofing of the study.

Syndicate content